Similar articles

• [Moniliasis prevention in newborn infants. II. Effectivity of general nystatin prevention in premature infants and hypotrophic newborn infants in a newborn intensive care unit].

  Schwarze R, Blaschke-Hellmessen R, Hinkel GK, Weigl I, Hoffmann H. Schwarze R, et al. Kinderarztl Prax. 1979 Mar;47(3):135-42. Kinderarztl Prax. 1979. PMID: 449178 German. No abstract available.
• [Examinations for the prevention of oral candidiasis in the newborn].

  Vörös J, Karányi G. Vörös J, et al. Orv Hetil. 1978 Feb 12;119(7):398-400. Orv Hetil. 1978. PMID: 625414 Hungarian. No abstract available.
• [Orally administered nystatin to newborn infants in the prevention of candidiasis].

  Blaschke-Hellmessen R, Schwarze R, Schmeiser H, Weigl I. Blaschke-Hellmessen R, et al. Z Gesamte Hyg. 1976 Jul;22(7):501-9. Z Gesamte Hyg. 1976. PMID: 960840 German. No abstract available.
• A reevaluation of nystatin in prophylaxis and treatment of oropharyngeal candidiasis.

  Alvarez Alvarez ME, Sánchez-Sousa A, Baquero F. Alvarez Alvarez ME, et al. Rev Esp Quimioter. 1998 Dec;11(4):295-315. Rev Esp Quimioter. 1998. PMID: 9990144 Review.
• [Newborn and premature infants. II].

  Ewerbeck H. Ewerbeck H. Monatsschr Kinderheilkd (1902). 1965 Aug;113(8):525-32. Monatsschr Kinderheilkd (1902). 1965. PMID: 5323230 Review. German. No abstract available.